Shorter infusion time of ocrelizumab: Results from the randomized, doubleblind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis von Hartung, HP, Berger, T, Bermel, RA, Brochet, B, Carroll, WM, Holmøy, Trygve, Karabudak, R, Killestein, J, Nos, C, Patti, Francesco, Ross, A, Vanopdenbosch, L, Vollmer, Timothy, Buffels, R, Garas, M, Kadner, Kathrin, Manfrini, M, Wang, Q, Freedman, M

Volltext